Table 2.

Treatment alternatives by level of care and sex.

	Primary care			Secondary care
	2005	2014	p	2005	2014	p
No MT	310 (40%)	311 (35%)	0.029	79 (25%)	95 (22%)	0.281
LAMA/SAMA	76 (10%)	108 (12%)	0.137	32 (10%)	46 (11%)	0.874
LABA	7 (1%)	13 (2%)	0.301	4 (1%)	8 (2%)	0.546
LAMA/SAMA + LABA	20 (3%)	19 (2%)	0.541	11 (4%)	12 (3%)	0.556
ICS	45 (6%)	21 (2%)	<0.0001	14 (4%)	10 (2%)	0.097
LABA + ICS	130 (17%)	113 (13%)	0.017	49 (16%)	47 (11%)	0.051
LAMA + LABA + ICS	187 (24%)	308 (35%)	<0.0001	125 (40%)	218 (50%)	0.006
	Male			Female
	2005	2014	p	2005	2014	p
No MT	165 (37%)	216 (37%)	0.894	224 (35%)	190 (26%)	<0.0001
LAMA/SAMA	50 (11%)	68 (12%)	0.780	58 (9%)	86 (12%)	0.
LABA	4 (1%)	9 (2%)	0.349	7 (1%)	12 (2%)	0.413
LAMA/SAMA + LABA	8 (2%)	11 (2%)	0.896	23 (4%)	20 (3%)	0.326
ICS	23 (5%)	17 (3%)	0.070	36 (6%)	14 (2%)	<0.0001
LABA + ICS	71 (16%)	72 (12%)	0.115	108 (17%)	88 (12%)	0.007
LAMA + LABA + ICS	130 (29%)	191 (33%)	0.181	182 (29%)	335 (45%)	<0.0001

Treatment with different medicines or combinations, in 2005 compared with 2014, distributed over sex and level of care. MT = maintenance treatment; LAMA = long-acting muscarinic antagonists; SAMA = short-acting muscarinic antagonists; LABA = long-acting beta-2-agonists; ICS = inhaled corticosteroids.